Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A broad and potent neutralization epitope in SARS-related coronaviruses
Meng Yuan, Xueyong Zhu, Wanting He, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 29
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Aekkachai Tuekprakhon, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, et al.
Cell (2022) Vol. 185, Iss. 14, pp. 2422-2433.e13
Open Access | Times Cited: 665
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Yanjia Chen, Xiaoyu Zhao, Hao Zhou, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 3, pp. 189-199
Open Access | Times Cited: 256
Monoclonal antibody therapies against SARS-CoV-2
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 197
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease
Pan-Pan Zhou, Ge Song, Hejun Liu, et al.
Immunity (2023) Vol. 56, Iss. 3, pp. 669-686.e7
Open Access | Times Cited: 106
Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis
Kaiming Tao, Philip L. Tzou, Sergei L. Kosakovsky Pond, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 4
Open Access | Times Cited: 76
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Aiste Dijokaite-Guraliuc, Raksha Das, Daming Zhou, et al.
Cell Reports (2023) Vol. 42, Iss. 4, pp. 112271-112271
Open Access | Times Cited: 37
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
Daniele Focosi, Scott A. McConnell, Arturo Casadevall
Drug Resistance Updates (2022) Vol. 65, pp. 100882-100882
Open Access | Times Cited: 40
Protective neutralizing epitopes in SARS‐CoV‐2
Hejun Liu, Ian A. Wilson
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 76-92
Open Access | Times Cited: 39
Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine
Yupeng Feng, Meng Yuan, John M. Powers, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 695
Open Access | Times Cited: 32
Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins
Laëtitia Misson, Hejun Liu, Gabriel Ozorowski, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 24
Open Access | Times Cited: 23
Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
William N. Voss, Michael L. Mallory, Patrick O. Byrne, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 8, pp. 101668-101668
Open Access | Times Cited: 7
Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
Chang Liu, Raksha Das, Aiste Dijokaite-Guraliuc, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
A Structural Voyage Toward the Landscape of Humoral and Cellular Immune Escapes of SARS‐CoV‐2
Jun Liu, Yan Wu, George F. Gao
Immunological Reviews (2025) Vol. 330, Iss. 1
Closed Access
Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-COV-2 Variants
Lingyan Cui, Tingting Li, Wenhui Xue, et al.
(2024)
Open Access | Times Cited: 5
Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants
Lingyan Cui, Tingting Li, Wenhui Xue, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 900-900
Open Access | Times Cited: 4
Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
Ailan Xu, Bixia Hong, Fuxing Lou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 24
The D Gene in CDR H3 Determines a Public Class of Human Antibodies to SARS-CoV-2
Meng Yuan, Ian A. Wilson
Vaccines (2024) Vol. 12, Iss. 5, pp. 467-467
Open Access | Times Cited: 3
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
Aline Almeida-Oliveira, Diana Freire, A. Andrade, et al.
Journal of Pharmaceutical Innovation (2023) Vol. 18, Iss. 3, pp. 1194-1212
Open Access | Times Cited: 10
Disulfide stabilization reveals conserved dynamic features between SARS-CoV-1 and SARS-CoV-2 spikes
Xixi Zhang, Zimu Li, Yanjun Zhang, et al.
Life Science Alliance (2023) Vol. 6, Iss. 9, pp. e202201796-e202201796
Open Access | Times Cited: 10
Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
William N. Voss, Michael Mallory, Patrick O. Byrne, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Epistasis between N-terminal and receptor-binding domains drives cell entry in a bat coronavirus spike
Alexandra L. Tse, Cory M. Acreman, Inna Ricardo-Lax, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift
Ge Song, Meng Yuan, Hejun Liu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 8
Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies
Christian Devaux, Jacques Fantini
Pathogens (2023) Vol. 12, Iss. 5, pp. 713-713
Open Access | Times Cited: 8
Glyco engineered pentameric SARS-CoV-2 IgMs show superior activities compared to IgG1 orthologues
Somanath Kallolimath, Roman Palt, Esther Föderl-Höbenreich, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor
Wan Ni Chia, Chee Wah Tan, Aaron Tan, et al.
Science Advances (2023) Vol. 9, Iss. 30
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top